New medications for diabetes
Pro Research Analysisby 
Searched over 200M research papers
New Medications for Diabetes: Recent Advances and Key Drug Classes
Insulin Innovations and New Formulations
Recent years have seen the development of new insulin types and delivery methods. Insulin degludec, a long-acting insulin, is now available for both type 1 and type 2 diabetes, offering more flexible dosing and potentially fewer hypoglycemic episodes. There are also new pre-mixed insulins, such as combinations of insulin degludec with insulin aspart, and research into methods to prolong the action of insulin glargine. Additionally, ultrarapid-acting insulins, including inhaled formulations and those mixed with hyaluronidase, are being explored to improve post-meal glucose control Garg2012Wu2019.
GLP-1 Receptor Agonists and Dual Agonists
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have become a cornerstone in diabetes management due to their ability to lower blood sugar, promote weight loss, and reduce cardiovascular risk. Newer agents, such as once-weekly exenatide and oral semaglutide, offer greater convenience. Dual agonists that target both GLP-1 and gastric inhibitory polypeptide (GIP) receptors, like tirzepatide, are showing even more impressive results for both glucose control and weight reduction, with effects similar to metabolic surgery Mingrone2022Sibony2023Nauck2021+1 MORE.
SGLT2 Inhibitors: Cardiovascular and Renal Benefits
Sodium-glucose cotransporter-2 (SGLT2) inhibitors are a newer class of oral medications that lower blood sugar by increasing glucose excretion in urine. These drugs not only improve glycemic control but also provide significant benefits for heart and kidney health, reducing the risk of heart failure and slowing the progression of chronic kidney disease Mingrone2022Blind2018Sibony2023+2 MORE.
DPP-4 Inhibitors and Other Oral Agents
Dipeptidyl peptidase-4 (DPP-4) inhibitors are another class of oral medications that help increase insulin release and decrease glucagon levels. While they are effective and have a low risk of hypoglycemia, they do not provide the same cardiovascular or weight loss benefits as GLP-1 RAs or SGLT2 inhibitors. Other emerging oral agents include glucokinase activators and drugs targeting new pathways, such as G-protein-coupled receptors and anti-inflammatory mechanisms Garg2012Wu2019Liao2012.
Novel and Future Therapies
Research is ongoing into new drug classes and regimens. For type 1 diabetes, immune-modulating drugs like teplizumab and cell therapies are under investigation. For type 2 diabetes, new agents such as high-dose oral semaglutide, orforglipron, retatrutide, and combination therapies like CagriSema and survodutide are in advanced clinical trials. These medications aim to further improve glycemic control, reduce complications, and address obesity, which is closely linked to type 2 diabetes .
Safety, Efficacy, and Individualized Treatment
Most new diabetes medications have demonstrated cardiovascular safety, and some have shown additional benefits such as reduced major adverse cardiovascular events and improved renal outcomes. However, the choice of therapy should be individualized, considering factors like efficacy, side effects, patient preferences, and comorbidities. Combination therapies and personalized approaches are increasingly important as the range of available medications expands Comi2015Blind2018Sibony2023+2 MORE.
Conclusion
The landscape of diabetes treatment is rapidly evolving, with new medications offering improved blood sugar control, weight loss, and protection against heart and kidney disease. Innovations in insulin, GLP-1 and GIP dual agonists, SGLT2 inhibitors, and other novel agents are expanding options for both type 1 and type 2 diabetes. As research continues, these advances promise better outcomes and more personalized care for people living with diabetes Garg2012Mingrone2022Blind2018+5 MORE.
Sources and full results
Most relevant research papers on this topic